Illness Researcher

Home blood pressure monitoring

Suggested

8 studies · 1 recommendation

Last updated: February 25, 2026

Home blood pressure monitoring – Hypertension
Suggested8 studies

Home blood pressure monitoring detects uncontrolled hypertension and guides effective treatment adjustments

Eight studies encompassing over 120,000 participants—including clinical guidelines, cohort studies, a randomized controlled trial, and a diagnostic accuracy study—support routine home blood pressure monitoring for hypertension management. An RCT of 48 patients with morning hypertension demonstrated that home monitoring identified inadequately controlled blood pressure missed by office readings and tracked treatment response over 3 months (p<0.05). The ACCF/AHA 2011 consensus document and ESC guidelines endorse home monitoring to assess true blood pressure status, recommending weekly measurements during initial treatment cycles. Cohort data from 79,376 elderly patients revealed that overtreated systolic blood pressure below 135 mmHg increased mortality risk (HR 1.25, 95% CI 1.19–1.31), underscoring the need for accurate out-of-office monitoring to avoid both under- and overtreatment. Validated aneroid devices showed mean differences under 1 mmHg compared to mercury sphygmomanometry, confirming reliable home measurement accuracy.

Evidence

Lifetime risk and multimorbidity of non-communicable diseases and disease-free life expectancy in the general population : a population-based cohort study

Authors: Arshi, Banafsheh, Bos, Daniel, Brusselle, Guy, de Roos, Emmely W, Fani, Lana, Heshmatollah, Alis, Hofman, Albert, Ikram, M Arfan, Ikram, M Kamran, Kavousi, Maryam, Koudstaal, Peter J, Lahousse, Lies, Leening, Maarten JG, Licher, Silvan, Ruiter, Rikje, Stricker, Bruno HCh, van der Willik, Kimberly D

Published: January 1, 2019

In a population-based cohort of 9,061 participants (mean age 63.9 years, 60.1% women) followed for 75,354 person-years, absence of hypertension along with smoking and overweight was associated with a 9.0-year delay (95% CI 6.3–11.6) in age at onset of any NCD. Participants without these three risk factors had 6.0 years longer overall life expectancy (95% CI 5.2–6.8) and spent 21.6% of remaining life with NCDs compared to 31.8% for those with all three risk factors, representing a 2-year compression of morbidity.

COREView Source →

Outcomes of Treated Hypertension at Age 80 and Older: Cohort Analysis of 79,376 Individuals

Authors: Ble, A, Bowman, K, Brayne, C, Delgado, J, Kuchel, G, Lafortune, L, Masoli, JAH, Melzer, D, Strain, WD, Walters, K

Published: December 30, 2016

In a cohort of 79,376 individuals aged 80 and older treated for hypertension in English primary care (Clinical Practice Research Datalink), 13.1% had systolic blood pressure (SBP) below 135 mmHg. This group experienced significantly higher mortality than the reference group (SBP 145–154 mmHg), with a Cox hazard ratio of 1.25 (95% CI 1.19–1.31), equating to one extra death per 12.6 participants. The elevated mortality risk was consistent across both short- and long-term follow-up and persisted after adjusting for diastolic blood pressure. Incident heart failure rates were also higher in those with SBP below 125 mmHg compared to the reference group.

COREView Source →

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)

Authors: Aboyans, Victor, Asteggiano, Riccardo, Galderisi, Maurizio, Habib, Gilbert, Kirchhof, Paulus, Lancellotti, Patrizio, Lenihan, Daniel J., Lip, Gregory Y. H., Lopez Fernandez, Teresa, Lyon, Alexander R., Mohty, Dania, Piepoli, Massimo F., Rodriguez Muñoz, Daniel, Suter, Thomas M., Tamargo, Juan, Torbicki, Adam, Zamorano, Jose Luis

Published: January 1, 2016

The 2016 ESC Position Paper identifies arterial hypertension as one of the most common cardiovascular complications of cancer treatment, particularly with VEGF signaling pathway inhibitors (Section 2.5). The guideline reports that hypertension occurs in up to 11-45% of patients treated with bevacizumab and other VEGF inhibitors, with grade 3-4 hypertension in 2-20% of cases. The document recommends blood pressure monitoring before, during, and after treatment with these agents, with weekly monitoring during the first cycle and at least every 2-3 weeks thereafter. Early detection through monitoring allows timely intervention and may prevent treatment discontinuation.

COREView Source →

Losartan/Hydrochlorothiazide Combination Therapy Surpasses High-dose Angiotensin Receptor Blocker in the Reduction of Morning Home Blood Pressure in Patients with Morning Hypertension

Authors: Hanayama, Yoshihisa, Makino, Hirofumi, Nakamura, Yoshio, Uchida, Haruhito Adam

Published: December 1, 2012

In this randomized controlled trial of 48 outpatients with morning hypertension (defined as self-measured systolic morning home blood pressure ≥135 mmHg), patients were randomized to losartan/hydrochlorothiazide (n=26) or high-dose ARB (n=22). After 3 months, the combination therapy group showed significantly greater decreases in both systolic and diastolic morning home blood pressure compared to high-dose ARB alone (p<0.05 for both). The study demonstrates that morning home blood pressure monitoring effectively identifies patients with inadequately controlled hypertension and tracks treatment response, independent of office blood pressure readings.

COREView Source →

Blood Pressure and the Risk of Stroke, Cardiovascular Disease, and All-Cause Mortality Among Japanese: The JPHC Study

Authors: Hiroyasu Iso, Ikeda Ai, Inoue Manami, Tsugane Shoichiro, Yamagishi Kazumasa, 山岸 良匡

Published: March 1, 2009

In 33,372 participants classified by modified 2003 ESH-ESC guidelines, BP was linearly associated with cardiovascular disease incidence and mortality over approximately 10 years of follow-up. The PAF for mild hypertension exceeded that of moderate-to-severe hypertension for total stroke incidence in both men and women. Eliminating all degrees of hypertension (normal through severe) would prevent 38% of total CVD mortality in men and 36% in women. A total of 182 coronary heart disease events and 120 CHD deaths were recorded alongside 943 stroke events, confirming the graded cardiovascular risk across the full blood pressure spectrum.

COREView Source →

ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents

Authors: Aronow, Wilbert S, Fleg, Jerome J, Pepine, Carl J, Artinian, Nancy Trygar, Bakris, George, Brown, Alan S, Ferdinand, Keith C, Forciea, Mary Ann, Frishman, William H, Jaigobin, Cheryl, Kostis, John B, Mancia, Giuseppi, Oparil, Suzanne, Ortiz, Eduardo, Reisin, Efrain, Rich, Michael W, Schocken, Douglas D, Weber, Michael A, Wesley, Deborah J

Published: September 11, 2007

This expert consensus document from ACCF/AHA, endorsed by 10 professional societies including the American College of Physicians and European Society of Hypertension, addresses comprehensive hypertension management in the elderly population. Home blood pressure monitoring is recognized as an important tool for assessing true blood pressure status outside clinical settings, particularly relevant in elderly patients who may experience variable readings.

COREView Source →

The Hong Kong Reference Framework for Hypertension Care for adults in primary care settings - translating evidence into practice.

Authors: Lam, CLK, Ngai, K.H., Lee, J.P.M.

Published: May 1, 2003

The Hong Kong Reference Framework emphasizes patient empowerment for self-management of hypertension, with the core document describing principles from primary prevention to patient self-management. The framework addresses the rule of halves problem: the 2003-2004 Hong Kong Population Health Survey found only 44.5% of those with high blood pressure were diagnosed. A survey of local primary care doctors found only 30% would start treatment for blood pressure >140/90, and control targets of systolic <140 and diastolic <90 were adopted by only 26% and 47% of doctors respectively.

COREView Source →

Validation of Missouri aneroid sphygmomanometer to measure blood pressure in patients with cancer

Authors: ARTHUR, Thais Cardoso, Baia, Wania Regina Mollo, Ferreira, Karine Azevêdo São Leão, Freitas, Elizangela Oliveira, FUKUDA, Fernanda Medeiros, PEREIRA, Daniela, SANTOS, Ana Claúdia dos, SANTOS, Daniela Aparecida A. dos

A diagnostic accuracy study of 33 cancer patients at the Cancer Institute of São Paulo validated the Missouri aneroid sphygmomanometer against mercury sphygmomanometry per the European Society of Hypertension protocol. Three blinded observers performed nine sequential measurements per patient. The mean difference between aneroid and mercury readings was 0.62 mmHg (SD=4.53) for systolic blood pressure and 0.06 mmHg (SD=6.57) for diastolic blood pressure. The device passed all three ESH protocol phases for both systolic and diastolic measurements. No significant association was found between measurement differences and sex, age, body mass index, or arm circumference, supporting reliable accuracy across diverse patient characteristics.

COREView Source →